logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
X

Xin-Rong Yang

fudan university
H指数:58
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation

靶向肿瘤内源性BCL9通过诱导巨噬细胞介导的吞噬作用和抗原呈递来逆转免疫治疗耐药性

Nature Communications
IF15.7
2025-11-170
OAAI
Sui-Yi Wu; Yuan-Yuan Zhu; Jia-Lei Sun; Chun-Yan Wang; Yu-Lei Wang; Yan-Yan Nie; Fei Song; Xun Huang; Zhong Chen; Tian He; Li-An Shen; Yang Xu; Cheng Huang; Shuang-Jian Qiu; Jian Zhou; Andrew X. Zhu; Jia Fan; Di Zhu; Bo Hu; Xin-Rong Yang
Exploring morphological heterogeneity of circulating tumor cells: machine learning-based approach for cell identification and prognostic implications

探索循环肿瘤细胞的形态异质性：基于机器学习的细胞识别方法及预后意义

Science Bulletin
IF21.1
2025-04-240
PRE
Peng-Xiang Wang; Yu-Chen Zhong; Bin Duan; Jian-Wen Cheng; Yun-Fan Sun; Wen-Jing Zheng; Kai-Qian Zhou; Yang Xu; Hai-Xiang Peng; Wei-Xiang Jin; Hai-Min Li; Xiao-Juan Sun; Wei Guo; Jian Zhou; Qi Liu; Jia Fan; Xin-Rong Yang
Efficacy and safety of rezvilutamide (Rez) plus androgen- deprivation therapy (ADT) in patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) aged ≤64, 65-74, and ≥75 years: Post-hoc analysis of randomized phase III CHART trial

瑞维卢他胺（Rez）联合雄激素剥夺疗法（ADT）在高体积、转移性、激素敏感的前列腺癌（mHSPC）患者中的疗效和安全性（年龄≤64岁、65-74岁和≥75岁）：随机III期CHART试验的事后分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Ye, D.; Bian, X.; Jiang, S.; Luo, H.; Zhou, F.; He, D.; Ma, L.; Guo, H.; Liang, C.; Chong, T.; Jiang, J.; Chen, Z.; Wang, Y.; Zou, Q.; Tian, Y.; Xiao, J.; Huang, J.; Yang, X.; Lian, J.; Wang, W.
An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte-tumor cell crosstalk, local immunosuppression and tumor progression
CELL RESEARCH
IF25.9
2023-06-1959
OAAI
Wu, Liang; Yan, Jiayan; Bai, Yinqi; Chen, Feiyu; Zou, Xuanxuan; Xu, Jiangshan; Huang, Ao; Hou, Liangzhen; Zhong, Yu; Jing, Zehua; Yu, Qichao; Zhou, Xiaorui; Jiang, Zhifeng; Wang, Chunqing; Cheng, Mengnan; Ji, Yuan; Hou, Yingyong; Luo, Rongkui; Li, Qinqin; Wu, Liang; Cheng, Jianwen; Wang, Pengxiang; Guo, Dezhen; Huang, Waidong; Lei, Junjie; Liu, Shang; Yan, Yizhen; Chen, Yiling; Liao, Sha; Li, Yuxiang; Sun, Haixiang; Yao, Na; Zhang, Xiangyu; Zhang, Shiyu; Chen, Xi; Yu, Yang; Li, Yao; Liu, Fengming; Wang, Zheng; Zhou, Shaolai; Yang, Huanming; Yang, Shuang; Xu, Xun; Liu, Longqi; Gao, Qiang; Tang, Zhaoyou; Wang, Xiangdong; Wang, Jian; Fan, Jia; Liu, Shiping; Yang, Xinrong; Chen, Ao; Zhou, Jian
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
Signal Transduction and Targeted Therapy
IF52.7
2023-03-170
OAAI
Guo-Ming Shi; Xiao-Yong Huang; Dong Wu; Hui-Chuan Sun; Fei Liang; Yuan Ji; Yi Chen; Guo-Huan Yang; Jia-Cheng Lu; Xian-Long Meng; Xin-Ying Wang; Lei Sun; Ning-Ling Ge; Xiao-Wu Huang; Shuang-Jian Qiu; Xin-Rong Yang; Qiang Gao; Yi-Feng He; Yang Xu; Jian Sun; Zheng-Gang Ren; Jia Fan; Jian Zhou

研究方向

暂未获取到该数据
樊
樊嘉
H 指数:126论文数:1,507被引数:6.8万
周
周箭
H 指数:104论文数:1,031被引数:4.6万
B
Bo Hu
H 指数:46论文数:159被引数:1.0万
Y
Yun‐Fan Sun
H 指数:32论文数:136被引数:6,661
J
Jian Zhou
H 指数:59论文数:476被引数:1.4万
郭维 封面图
郭维
H 指数:48论文数:267被引数:1.3万
J
Jianwen Cheng
H 指数:23论文数:77被引数:1,821
B
Beili Wang
H 指数:29论文数:185被引数:2,562
Y
Yang Xu
H 指数:39论文数:92被引数:7,582
A
Ao Huang
H 指数:24论文数:67被引数:2,970